159 related articles for article (PubMed ID: 2680669)
1. Different daily blood glucose control and free insulin levels during treatment with mixtures of soluble and lente or soluble and NPH semisynthetic human insulins.
Cucinotta D; Di Benedetto A; Gigante A; Di Cesare E; Musolino C; Squadrito G
Diabete Metab; 1989; 15(4):182-7. PubMed ID: 2680669
[TBL] [Abstract][Full Text] [Related]
2. Miscibility of human semisynthetic regular and lente insulin and human biosynthetic regular and NPH insulin.
Olsson PO; Hans A; Henning VS
Diabetes Care; 1987; 10(4):473-7. PubMed ID: 3304898
[TBL] [Abstract][Full Text] [Related]
3. The contribution of intermediate-acting insulin preparations to daytime insulin treatment.
Robert JJ; Chevenne D; Debray M
Diabet Med; 1989 Aug; 6(6):531-6. PubMed ID: 2527136
[TBL] [Abstract][Full Text] [Related]
4. Absorption kinetics and action profiles of mixtures of short- and intermediate-acting insulins.
Heine RJ; Bilo HJ; Fonk T; van der Veen EA; van der Meer J
Diabetologia; 1984 Dec; 27(6):558-62. PubMed ID: 6397384
[TBL] [Abstract][Full Text] [Related]
5. Double-blind crossover trial of isophane (NPH)- and lente-based insulin regimens.
Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I
Diabetes Care; 1989 Feb; 12(2):115-9. PubMed ID: 2649324
[TBL] [Abstract][Full Text] [Related]
6. Mixtures of human intermediate and human regular insulin in type 1 diabetic patients. Evaluation of free insulin levels and insulin action on glucose metabolism after combined and separate subcutaneous administration.
Klauser R; Schernthaner G; Prager R
Diabetes Res Clin Pract; 1988 Sep; 5(3):185-90. PubMed ID: 3065016
[TBL] [Abstract][Full Text] [Related]
7. The effect of insulin mixtures in type I diabetics: influence of the intermediate acting insulin on the action of short acting insulin.
Goicolea I; Quiroga A; Vazquez JA
Diabete Metab; 1987; 13(4):467-70. PubMed ID: 3315768
[TBL] [Abstract][Full Text] [Related]
8. A comparison of human ultralente- and lente-based twice-daily injection regimens.
Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I
Diabet Med; 1989 Aug; 6(6):496-501. PubMed ID: 2527130
[TBL] [Abstract][Full Text] [Related]
9. Intermediate-acting insulin preparations: NPH and lente.
Deckert T
Diabetes Care; 1980; 3(5):623-6. PubMed ID: 7192205
[TBL] [Abstract][Full Text] [Related]
10. Split-mixed insulin regimen with human ultralente before supper and NPH (isophane) before breakfast in children and adolescents with IDDM.
Wolfsdorf JI; Laffel LM; Pasquarello C; Vernon A; Herskowitz RD
Diabetes Care; 1991 Nov; 14(11):1100-6. PubMed ID: 1797498
[TBL] [Abstract][Full Text] [Related]
11. Improvement of basal hepatic glucose production and fasting hyperglycemia of type I diabetic patients treated with human recombinant ultralente insulin.
Riccio A; Avogaro A; Valerio A; Zappella A; Tiengo A; Del Prato S
Diabetes Care; 1994 Jun; 17(6):535-40. PubMed ID: 8082521
[TBL] [Abstract][Full Text] [Related]
12. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.
Hermansen K; Fontaine P; Kukolja KK; Peterkova V; Leth G; Gall MA
Diabetologia; 2004 Apr; 47(4):622-9. PubMed ID: 15298338
[TBL] [Abstract][Full Text] [Related]
13. Soluble and Lente human insulin mixtures in normal man.
Owens DR; Vora JP; Jones IR; Birtwell J; Atiea J; Luzio S; Williams S
Diabetes Res; 1988 Jan; 7(1):35-40. PubMed ID: 3042252
[TBL] [Abstract][Full Text] [Related]
14. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
[TBL] [Abstract][Full Text] [Related]
15. [Advances in insulin treatment. Evaluation of isophane or lente insulin, mixed with rapid insulin and injected twice-a-day].
Cucinotta D; Lunetta M
Minerva Endocrinol; 1990; 15(2):111-6. PubMed ID: 2098651
[TBL] [Abstract][Full Text] [Related]
16. Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen.
Nielsen FS; Jørgensen LN; Ipsen M; Voldsgaard AI; Parving HH
Diabetologia; 1995 May; 38(5):592-8. PubMed ID: 7489843
[TBL] [Abstract][Full Text] [Related]
17. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
Russell-Jones D; Simpson R; Hylleberg B; Draeger E; Bolinder J
Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
[TBL] [Abstract][Full Text] [Related]
18. Comparison of glycemic variability associated with insulin glargine and intermediate-acting insulin when used as the basal component of multiple daily injections for adolescents with type 1 diabetes.
White NH; Chase HP; Arslanian S; Tamborlane WV;
Diabetes Care; 2009 Mar; 32(3):387-93. PubMed ID: 19106380
[TBL] [Abstract][Full Text] [Related]
19. Miscibility of semisynthetic human ultralente insulin with short-acting insulin in insulin-dependent diabetic patients.
Lunetta M; di Mauro M; Crimi S; Sudano L; Mughini L
Acta Diabetol Lat; 1988; 25(3):263-9. PubMed ID: 3071068
[TBL] [Abstract][Full Text] [Related]
20. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin.
Porcellati F; Rossetti P; Pampanelli S; Fanelli CG; Torlone E; Scionti L; Perriello G; Bolli GB
Diabet Med; 2004 Nov; 21(11):1213-20. PubMed ID: 15498088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
